Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sbitti, Yassir, Essaidi l, Ismail, Debbagh, Adil, Kadiri, Habiba, Oukabli, Mohamed, Moussaid, Yassine, Slimani, Khaoula, Fetohi, Mohamed, Elkaoui, Hakim, Albouzidi, Abderrahmane, Mahi, Mohamed, Ali, Abdelmounaim Ait, Ichou, Mohamed, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204255/
https://www.ncbi.nlm.nih.gov/pubmed/21955806
http://dx.doi.org/10.1186/1477-7819-9-112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204255/
https://www.ncbi.nlm.nih.gov/pubmed/21955806
http://dx.doi.org/10.1186/1477-7819-9-112

Ejemplares similares